Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 15, 2015 9:30 AM - Nov 17, 2015 5:45 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

12th Annual Meeting DIA Japan 2015

The registrants will have access to presentation PDFs through Tuesday, May 17, 2016.

[V2-S2] ICH E14: Update on Current Status and Future Directions of Cardiac Safety Assessment

Session Chair(s)

Boaz  Mendzelevski, MD

Boaz Mendzelevski, MD

Consultant Cardiologist

Cardiac Safety Consultants Ltd., United Kingdom

Drug-induced QT prolongation may lead to cardiac arrhythmia and sudden cardiac death, and has resulted in the withdrawal and non-approval of several drugs. The regulatory response to concerns regarding the cardiac safety of new drugs also led to the development of the ICH S7B (non-clinical) and ICH E14 (clinical) guidelines. The hallmark of the ICH E14 guideline is the Thorough QT (TQT) study. Recently, an early phase Intensive QT (IQT) clinical assessment, using exposure response (ER) modeling as its primary analysis, was advocated as an alternative to the TQT study and is currently under regulatory discussions. In a separate initiative, presently under development, the US FDA proposed a platform of non-clinical investigations, the ‘Comprehensive Pro-arrhythmia In vitro Assay’ (CiPA), as a replacement for the above guidelines. This session will provide an introduction to cardiac safety and an overview of the current and future clinical research and regulatory landscape in Japan and globally.

Speaker(s)

Atsushi  Sugiyama, MD, PhD

Drug-induced QT Prolongation: From Ion Channels and Cardiac Arrhythmia to Regulatory Guidance

Atsushi Sugiyama, MD, PhD

Toho University Faculty of Medicine, Japan

Professor and Chairman, Department of Pharmacology

Kaori  Shinagawa, MD, PhD

The ICH E14 Guideline: Overview of its Status in Japan and Future Directions

Kaori Shinagawa, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Senior Scientist for Clinical Medicine, Office of New Drug II

Boaz  Mendzelevski, MD

QT Assessment in Clinical Drug Development: Are We There Yet?

Boaz Mendzelevski, MD

Cardiac Safety Consultants Ltd., United Kingdom

Consultant Cardiologist

Yuji  Kumagai, MD, PhD

Yuji Kumagai, MD, PhD

Kitasato University Hospital, Japan

Professor, Kitasato Clinical Research Center

Koki  Nakamura, MD, PhD

Koki Nakamura, MD, PhD

Takeda Pharmaceutical Company Limited, Japan

Vice President, CVM Marketing, Japan Pharma Business Unit

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.